These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 7514856)

  • 1. Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase.
    Zhang D; Caliendo AM; Eron JJ; DeVore KM; Kaplan JC; Hirsch MS; D'Aquila RT
    Antimicrob Agents Chemother; 1994 Feb; 38(2):282-7. PubMed ID: 7514856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
    Gu Z; Gao Q; Fang H; Salomon H; Parniak MA; Goldberg E; Cameron J; Wainberg MA
    Antimicrob Agents Chemother; 1994 Feb; 38(2):275-81. PubMed ID: 7514855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.
    Gu Z; Gao Q; Li X; Parniak MA; Wainberg MA
    J Virol; 1992 Dec; 66(12):7128-35. PubMed ID: 1279198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs.
    Gu Z; Arts EJ; Parniak MA; Wainberg MA
    Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2760-4. PubMed ID: 7535930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro.
    Gu Z; Fletcher RS; Arts EJ; Wainberg MA; Parniak MA
    J Biol Chem; 1994 Nov; 269(45):28118-22. PubMed ID: 7525567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine.
    Medlin HK; Zhu YQ; Remington KM; Phillips TR; North TW
    Antimicrob Agents Chemother; 1996 Apr; 40(4):953-7. PubMed ID: 8849258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
    Rusconi S; La Seta Catamancio S; Sheridan F; Parker D
    J Clin Virol; 2000 Dec; 19(3):135-42. PubMed ID: 11090748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
    Larder BA; Kohli A; Bloor S; Kemp SD; Harrigan PR; Schooley RT; Lange JM; Pennington KN; St Clair MH
    J Virol; 1996 Sep; 70(9):5922-9. PubMed ID: 8709213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.
    Eron JJ; Chow YK; Caliendo AM; Videler J; Devore KM; Cooley TP; Liebman HA; Kaplan JC; Hirsch MS; D'Aquila RT
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1480-7. PubMed ID: 7689822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M; Kemp SD; Parry NR; Larder BA
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5'-triphosphate beta enantiomers of cytidine analogs.
    Faraj A; Agrofoglio LA; Wakefield JK; McPherson S; Morrow CD; Gosselin G; Mathe C; Imbach JL; Schinazi RF; Sommadossi JP
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2300-5. PubMed ID: 7530932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides.
    Smith RA; Remington KM; Lloyd RM; Schinazi RF; North TW
    J Virol; 1997 Mar; 71(3):2357-62. PubMed ID: 9032372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase.
    Boucher CA; Cammack N; Schipper P; Schuurman R; Rouse P; Wainberg MA; Cameron JM
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2231-4. PubMed ID: 7504909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates.
    Nájera I; Richman DD; Olivares I; Rojas JM; Peinado MA; Perucho M; Nájera R; López-Galíndez C
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1479-88. PubMed ID: 7534096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture.
    Lacey SF; Larder BA
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1428-32. PubMed ID: 7522429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine.
    Fitzgibbon JE; Howell RM; Haberzettl CA; Sperber SJ; Gocke DJ; Dubin DT
    Antimicrob Agents Chemother; 1992 Jan; 36(1):153-7. PubMed ID: 1317143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational analysis of Lys65 of HIV-1 reverse transcriptase.
    Sluis-Cremer N; Arion D; Kaushik N; Lim H; Parniak MA
    Biochem J; 2000 May; 348 Pt 1(Pt 1):77-82. PubMed ID: 10794716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
    Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
    AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study.
    Shirasaka T; Yarchoan R; O'Brien MC; Husson RN; Anderson BD; Kojima E; Shimada T; Broder S; Mitsuya H
    Proc Natl Acad Sci U S A; 1993 Jan; 90(2):562-6. PubMed ID: 8380641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunodeficiency virus 1 strains resistant to nucleoside inhibitors of reverse transcriptase in isolates from the Czech Republic as monitored by line probe assay and nucleotide sequencing.
    Reinis M; Vandasová J; Stanková M; Linka M; Brůcková M
    Acta Virol; 2001; 45(5-6):279-86. PubMed ID: 12083326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.